The Role of Factor Xa Anticoagulation in the Treatment of Venous and Arterial Diseases

The Role of Factor Xa Anticoagulation in the Treatment of Venous and Arterial Diseases

On-Demand Webcast

Constantino Peña, MD, FSIR
Miami Cardiac & Vascular Institute
Miami, Florida

Jose Almeida, MD, FACS
Miami Vein Center
Miami, Florida

Anthony Comerota, MD, FACS, FACC
Eastern Region Heart and Vascular Institute
Inova Medical Group
Alexandria, Virginia

William Gray, MD, FACC, FSCAI
Main Line Health
President, Lankenau Heart Institute
Wynnewood, Pennsylvania

Raghu Kolluri, MD, MS, RVT, FSVM
OhioHealth Riverside Methodist Hospital
Columbus, Ohio


Provided by North American Center for Continuing Medical Education, LLC, an HMP Company and The University of Cincinnati 

For questions regarding this educational activity, please call 609-371-1137 or email


This activity is designed for Interventional radiologists, vascular surgeons, interventional cardiologists, cardiothoracic surgeons, clinical cardiologists, clinical radiologists, internists, nurses and others involved in the treatment of cardiovascular disease in both veins and arteries.


After participating in this activity, participants should be better able to:

  • Identify the clinical and socioeconomic factors that contribute to the public health burden associated with venous and arterial diseases
  • Describe the Xa inhibitor mechanism of action and the associated rationale for its use in VTE and PAD management
  • Evaluate the clinical evidence and current guidelines surrounding the use of Xa inhibitors for the short-long-term, and extended prophylaxis of VTE and PAD across care settings
  • Integrate the latest guidance and clinical data into interdisciplinary, patient-centric care plans for the use of Xa inhibitors in treatment and prevention of VTE and PAD

To be eligible for credit, participants must complete the online activity, a post-test assessment, and the evaluation by February 28, 2021. Upon completing the activity, there will be instructions on how to print a certificate or other documentation of credit.

Release Date: February 28, 2020
Expiration Date: February 28, 2021
Estimated Time to Complete: 1 hour

There is no fee associated with this activity.


NACCME would like to thank the following company who has supported the "The Role of Factor Xa Anticoagulation in the Treatment of Venous and Arterial Diseases"  through educational grants and/or in-kind support: Janssen Scientific Affairs, LLC


    In support of improving patient care, NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians. The University of Cincinnati designates this live activity for a maximum of 1 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


The American Medical Association (AMA) has an agreement of mutual recognition of CME credit with the European Union of Medical Specialists (UEMS). Under the terms of this agreement the European Accreditation Council for Continuing Medical Education (EACCME), the accrediting arm of the UEMS, will convert CME credit for live activities certified by the AMA.


This continuing nursing education activity awards 1.00 contact hour.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.00 contact hour. 


NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 credit. PAs should only claim credit commensurate with the extent of their participation.


This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.


This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME.


The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither NACCME nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.

The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or HMP, and The University of Cincinnati. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.


NACCME, LLC is an independent provider(s) of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

NACCME, LLC assures that all educational materials are reviewed to ensure for the absence of commercial bias, fair balance, scientific objectivity, and levels of evidence. The educational activity will not be influenced by commercial organizations and will not conflict with any other scheduled educational activities.

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

Clinical Reviewers

Adam Geronemus, MD
Interventional Radiologist
Miami Cardiac & Vascular Institute
South Miami Heart Center
Miami, Florida

Alex Powell, MD
Interventional Radiologist
Miami Cardiac & Vascular Institute
Miami, Florida

Brian Schiro, MD
Interventional Radiologist
Miami Cardiac & Vascular Institute
Miami, Florida

Susie Seaman, NP
Sharp Rees-Stealy Wound Clinic
San Diego, California

Planning Committee

In addition to the faculty listed below, the planning committee is comprised of: James Benenati, MD, FSIR; Daniel Clair, MD; Ripal T. Gandhi, MD, FSIR, FVSM; Adam Geronemus, MD; William Gray, MD, FACC, FSCAI; Barry Katzen, MD, FACC, FACR, FSIR; Kenia Lynn, PA; Jihad Mustapha, MD, FACC, FSCAI; Richard Neville, MD, FACS; Constantino Peña, MD, FSIR; Alex Powell, MD, FSIR; Ramon Quesada, MD; Brian Schiro, MD; and Susie Seaman, NP; and Chris Bolwell, Caitlin Eastman, MaryEllen Fama, Jennifer Ilcyn, Todd Kunkler, Joanna Tong, and Colleen Waters, NACCME; Bruce Gebhart, Barbara Forney, University of Cincinnati.

Chris Bolwell is a shareholder of GlaxoSmithKline. GlaxoSmithKline is not supporting this activity, nor does any content relate to their product/service.

Ms. Fama, Ms. Ilcyn, Mr. Kunkler, Ms. Tong, and Ms. Waters of NACCME have disclosed no relevant financial relationships with any commercial interests.

The faculty has reported the following:

Constantino Peña: Speakers’ Bureau–Penumbra, Boston Scientific, Cook Medical, CR Bard BD, Abbott Vascular

Anthony Comerota: Consultant – Janssen; Speakers’ Bureau– BMS/Sanofi

William Gray: Consultant –  Boston Scientific, Cook Medical, Gore, Medtronic, Shockwave and Abbottt Vascular; Grant/Research Support –  Abbott Vascular, Boston Scientific, Gore, Intact Vascular and Shockwave; Stocks –  Biocardia, Contego Medical and Silk Road.

Jose Almeida and Raghu Kolluri have disclosed no relevant financial relationships with any commercial interests.


North American Center for Continuing Medical Education (NACCME) complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.


NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2020 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.